Table 2.
Healthy Control characteristics
| Control males |
Control females |
||||||
|---|---|---|---|---|---|---|---|
| HLA Class IIb |
HLA Class II |
||||||
| Study ID |
Agea |
DRB1 |
DQB1 |
Study ID |
Age |
DRB1 |
DQB1 |
| 12 | 45 | -c | - | 8 | 26 | - | - |
| 22 | 35 | - | - | 10 | 27 | 3,7 | 2 |
| 28 | 30 | - | - | 21 | 48 | 13,15 | 6,6 |
| 32 | 25 | - | - | 23 | 30 | - | - |
| 35 | 45 | 15,1 | 5,6 | 24 | 25 | - | - |
| 38 | 40 | - | - | 25 | 24 | - | - |
| 47 | 34 | 15,7 | 6,2 | 27 | 45 | - | - |
| 49 | 44 | - | - | 30 | 38 | 4,16 | 3,5 |
| 56 | 34 | 13,4 | 3,6 | 36 | 39 | 4,11 | 3 |
| 62 | 42 | - | - | 39 | 35 | 15 | 6 |
| 65 | 22 | - | - | 40 | 48 | 1,3 | 5,6 |
| 66 | 21 | - | - | 41 | 45 | 3,11 | 2,3 |
| 68 | 24 | 1,3 | 5,2 | 42 | 34 | 15 | 6 |
| 71 | 45 | 7,4 | 2,3 | 43 | 33 | 3,13 | 2,6 |
| 72 | 32 | 3,4 | 3,2 | 51 | 50 | 4 | 3 |
| 73 | 22 | - | - | 53 | 47 | 3 | 2 |
| 79 | 41 | 3,11 | 2,3 | 55 | 50 | 13,14 | 5,6 |
| 80 | 48 | 4,7 | 3,2 | 58 | 36 | - | - |
| 84 | 24 | 10,11 | 3,5 | 59 | 20 | 1,13 | 5,3 |
| 94 | 40 | 4,13 | 3,6* | 70 | 44 | - | - |
| 96 | 27 | 4,15* | 3,6* | 75 | 27 | - | - |
| 100 | 40 | 11,13 | 6*,6 | 77 | 55 | 3,15 | 2,6 |
| 101 | 41 | - | - | 82 | 48 | 1,3 | 5,2 |
| 102 | 52 | - | - | 86 | 36 | 11,15 | 3,6 |
| 108 | 39 | 3,15* | 4,6 | 88 | 30 | 3 | 2 |
| 111 | 25 | 14,15 | 5,6* | 89 | 38 | 15 | 6 |
| 114 | 38 | 4,7 | 3,2 | 90 | 51 | 3,4 | 3,2 |
| 120 | 39 | 4,15 | 3,6 | 91 | 35 | 4,13 | 3 |
| 125 | 41 | 11,14 | 3,5 | 92 | 28 | 3,4 | 2,3 |
| 129 | 29 | 11,15 | 3,6 | 93 | 38 | 11,16 | 5,6 |
| 132 | 27 | 3,4 | 2,4 | 95 | 21 | 15* | 6 |
| 150 | 39 | 15 | 6 | 98 | 43 | 11,15* | 6 |
| 152 | 36 | 1 | 5 | 104 | 48 | - | - |
| 159 | 24 | 11,13 | 3,6* | 109 | 43 | 11,13 | 5,3 |
| 161 | 41 | 11,13 | 3,6 | 115 | 31 | 3,15 | 2,6 |
| 162 | 24 | 11,15 | 3,6 | 116 | 41 | 4,11 | 3,3 |
| 163 | 39 | 13,15 | 3,6 | 118 | 49 | 11,15 | 3,6 |
| 164 | 42 | 4,12 | 3,3 | 124 | 51 | - | - |
| 165 | 29 | 4,15 | 3,6 | 128 | 46 | 1,9 | 5,2 |
| 172 | 54 | 7,13 | 2,6* | 136 | 33 | 11 | 6 |
| 173 | 28 | 13 | 6* | 137 | 55 | 7,15 | 2,6 |
| 144 | 42 | 11,3 | 2,3 | ||||
| 154 | 34 | 7,12 | 3,3 | ||||
| 155 | 36 | 7 | 2 | ||||
| 156 | 27 | 1,15 | 5,6 | ||||
| 157 | 36 | 3,15 | 2,6 | ||||
| 166 | 34 | 1,10 | 5 | ||||
| 167 | 30 | 7,8 | 2,4 | ||||
| 168 | 45 | 1,15 | 5,6 | ||||
| 169 | 26 | 4,15 | 3,6 | ||||
| 170 | 29 | 1,3 | 2,5 | ||||
| 171 | 49 | 15,15* | 6,6 | ||||
| 181 | 45 | 1 | 5 | ||||
a
Average ages: Control males (CM), 35.4 ± 8.8 yrs : Control females (CF), 38.2 ± 9.3 yrs.
b
HLA Class II lists both alleles separated by a comma (homozygous individuals have only one number). Four-digit molecular HLA typing has been simplified to 2 digits (e.g. *1501 is shortened to 15; *1301 is 13; *0401 is 4; *0101 is 1; *0301 is 3). Numbers followed by “*” are allelic variants: 1* is *0103 (not the same as *0101); 15* is 1503, an allelic variation that is rare in Caucasians; 6* is *0602 but ambiguities exist with 0619 and 0620. Representations of HLA types: DR15: CM 31%; CF 33%; DR4: CM 38%; CF 19%; DR3: CM 17%; CF 30%.
c
Dashes are data that were not tested or unavailable.